Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 11/20 | 0.68 |
| ▸ | JAK1 | P23458 | 2/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.47 |
| ▸ | AKT2 | P31751 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3532381 | 0.82 | JAK3 (1.00) | JAK3JAK1JAK2TRPA1HPGDS | |
| SCHEMBL15856566 | 0.81 | JAK3 (0.59) | JAK3JAK1JAK2 | |
| SCHEMBL17545940 | 0.77 | JAK1 (0.57) | JAK3JAK1JAK2 | |
| SCHEMBL17545945 | 0.76 | JAK3 (0.73) | JAK3JAK1JAK2TRPA1HPGDS | |
| SCHEMBL20183342 | 0.75 | JAK3 (0.76) | JAK3JAK1JAK2AKT2GSK3B | |
| SCHEMBL1980392 | 0.74 | JAK3 (0.74) | JAK3JAK1JAK2TRPA1HPGDS | |
| SCHEMBL18419031 | 0.74 | BTK (0.69) | — | |
| SCHEMBL15856585 | 0.73 | JAK3 (0.51) | JAK3JAK1JAK2 | |
| SCHEMBL20183344 | 0.72 | JAK3 (0.59) | JAK3JAK1JAK2 | |
| SCHEMBL17545928 | 0.71 | BTK (0.71) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. | 2017-02-02 | — | — | US | disclosed |
| US-9273028-B2 | Heterocyclic tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2016-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | TEC, ABL1, LCK | JAK3 154/4885JAK1 120/4885JAK2 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.